Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs APGE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APGE Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–0 Matrix Metrics)

APGE Overall Winner 6-Pillar Tally: PVLA 1 – 3 APGE (2 Tie) Matrix Metrics: PVLA 0 – 5 APGE

As of Nov 16, 2026, Apogee Therapeutics, Inc. (APGE) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas APGE carries 54.9/100 (HOLD) at $135.07 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs APGE
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
APGE NASDAQ Head-to-Head Winner
Apogee Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$135.07
-0.01% 1D
Market Cap $10.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 1% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 49.0 Fund 52.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (15.7% over 20 days), RSI 77
RSI-14: 77.4 · SMA20: $134.77 · SMA50: $134.13

6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 3 APGE)

Columns: Metric · PVLA · APGE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale APGE
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $2.2B $10.2B
3. Profitability & Quality APGE
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.4% -32.5%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$43M -$244M
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $99M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning APGE
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 47.9% (2nd %ile) 1.9% (1st %ile)
Put/Call OI Skew 3.82x (Put-Skewed) 0.22x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (0) vs APGE (5)
Institutional Metric PVLA APGE Criterion Row Edge
Market Capitalization
Scale
$2.2B $10.2B Larger Scale APGE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.4% -32.5% Higher ROE APGE
52-Week Range Position
Momentum
68% ($72–$180) 100% ($35–$135) Stronger Trend APGE
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 0.71β · 1% Vol Lower Realized Risk APGE
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite APGE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$244M ($99M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon Tie
PVLA: +0.63% · APGE: +0.66%
3M Horizon APGE +27.91 pp
PVLA: +32.52% · APGE: +60.43%
6M Horizon APGE +73.9 pp
PVLA: +12.89% · APGE: +86.79%
1Y Horizon APGE +24.5 pp
PVLA: +90.0% · APGE: +114.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs APGE. Trailing 12-month operating profitability (PVLA 0.0% vs APGE 0.0%) and valuation multiples (PVLA N/M vs APGE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M
APGE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-32.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APGE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 1.9%
IV Percentile 1st %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact APGE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
APGE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs APGE Key Questions & Quantitative Answers

As of Nov 16, 2026, Apogee Therapeutics, Inc. (APGE) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas APGE carries 54.9/100 (HOLD) at $135.07 (N/M Forward P/E, 0.0% operating margin). Technically, PVLA sits in a Neutral phase (RSI 50.9, CONSOLIDATION options structure) and APGE sits in a Markup phase (RSI 77.4, UNCLASSIFIED options structure).

APGE leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with APGE at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus N/A for APGE. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APGE.

PVLA and APGE trade at balanced relative valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas APGE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus APGE (-32.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, APGE carries 1.9% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 1% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.